Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPIX NASDAQ:LIXT NASDAQ:SNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPIXCumberland Pharmaceuticals$6.75+13.3%$5.10$1.85▼$6.75$89.30M0.0947,515 shs93,232 shsLIXTLixte Biotechnology$7.19+8.1%$5.63$0.68▼$7.78$99.88M1.27402,054 shs213,996 shsSNGXSoligenix$0.41+3.8%$0.59$0.28▼$6.23$5.86M1.843.00 million shs642,483 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPIXCumberland Pharmaceuticals-1.49%+4.20%+3.29%+94.14%+133.73%LIXTLixte Biotechnology-3.20%-12.61%+17.70%+115.21%+752.56%SNGXSoligenix+1.02%-1.13%-23.00%-65.04%-70.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPIXCumberland Pharmaceuticals$6.75+13.3%$5.10$1.85▼$6.75$89.30M0.0947,515 shs93,232 shsLIXTLixte Biotechnology$7.19+8.1%$5.63$0.68▼$7.78$99.88M1.27402,054 shs213,996 shsSNGXSoligenix$0.41+3.8%$0.59$0.28▼$6.23$5.86M1.843.00 million shs642,483 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPIXCumberland Pharmaceuticals-1.49%+4.20%+3.29%+94.14%+133.73%LIXTLixte Biotechnology-3.20%-12.61%+17.70%+115.21%+752.56%SNGXSoligenix+1.02%-1.13%-23.00%-65.04%-70.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPIXCumberland Pharmaceuticals 1.00SellN/AN/ALIXTLixte Biotechnology 1.00SellN/AN/ASNGXSoligenix 2.00Hold$6.001,363.41% UpsideCurrent Analyst Ratings BreakdownLatest SNGX, CPIX, and LIXT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026CPIXCumberland Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/26/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SNGXSoligenix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026CPIXCumberland Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPIXCumberland Pharmaceuticals$44.52M2.27$0.42 per share16.25$1.64 per share4.12LIXTLixte BiotechnologyN/AN/AN/AN/A$1.05 per shareN/ASNGXSoligenix$120K50.64N/AN/A$0.52 per share0.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPIXCumberland Pharmaceuticals-$2.84M-$0.49N/AN/AN/A-17.60%-12.01%-4.24%8/11/2026 (Estimated)LIXTLixte Biotechnology-$6.01M-$1.13N/AN/AN/AN/A-134.91%-95.61%N/ASNGXSoligenix-$11.08M-$1.68N/AN/AN/AN/A-244.73%-131.22%8/13/2026 (Estimated)Latest SNGX, CPIX, and LIXT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LIXTLixte BiotechnologyN/A-$0.18N/A-$0.18N/AN/A5/8/2026Q1 2026SNGXSoligenix-$0.30-$0.28+$0.02-$0.28N/AN/A5/5/2026Q1 2026CPIXCumberland Pharmaceuticals-$0.13-$0.13N/A-$0.22$8.50 million$9.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCPIXCumberland PharmaceuticalsN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPIXCumberland Pharmaceuticals0.250.950.79LIXTLixte BiotechnologyN/A2.782.78SNGXSoligenixN/A1.811.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPIXCumberland Pharmaceuticals15.51%LIXTLixte Biotechnology5.10%SNGXSoligenix3.60%Insider OwnershipCompanyInsider OwnershipCPIXCumberland Pharmaceuticals42.07%LIXTLixte Biotechnology9.50%SNGXSoligenix3.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPIXCumberland Pharmaceuticals8014.98 million8.68 millionOptionableLIXTLixte Biotechnology415.02 million13.59 millionNot OptionableSNGXSoligenix2014.82 million14.37 millionNot OptionableSNGX, CPIX, and LIXT HeadlinesRecent News About These CompaniesSoligenix Expands At-the-Market Equity Offering Capacity4 hours ago | tipranks.comSoligenix Inc. (NASDAQ:SNGX) Short Interest Down 92.6% in JuneJune 26 at 4:01 AM | americanbankingnews.comSoligenix Applying for Vaccine Development Funding for Bundibugyo Ebola VaccineJune 8, 2026 | prnewswire.comSoligenix Expands At-The-Market Equity Financing CapacityMay 28, 2026 | tipranks.comSNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail FrenzyMay 27, 2026 | finance.yahoo.comSuitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in CongoMay 26, 2026 | prnewswire.comSOLIGENIX, INC.: Soligenix Announces Recent Updates and First Quarter 2026 Financial ResultsMay 8, 2026 | finanznachrichten.deSoligenix Announces Recent Updates and First Quarter 2026 Financial ResultsMay 8, 2026 | prnewswire.comSNGX stock slumps to record low after lymphoma trial fails – all eyes now on Behçet’s disease treatmentApril 29, 2026 | msn.comSNGX phase 3 trial halted on HyBryteApril 29, 2026 | msn.comSOLIGENIX, INC.: Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte in Treatment of Cutaneous T-Cell LymphomaApril 28, 2026 | finanznachrichten.deSNGX phase 3 trial halted — HyBryte setback puts strategy in questionApril 28, 2026 | msn.comSoligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell LymphomaApril 28, 2026 | prnewswire.comSoligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation ApproachApril 23, 2026 | finance.yahoo.comSoligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation ApproachApril 23, 2026 | usatoday.comSoligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan StatusApril 20, 2026 | financial-news.co.ukSoligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan StatusApril 20, 2026 | finance.yahoo.comSoligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study ResultsApril 17, 2026 | financial-news.co.ukSoligenix (SNGX) Advances CTCL Research With Interim Analysis, Comparative Study ResultsApril 17, 2026 | finance.yahoo.comSoligenix (SNGX) price target decreased by 14.29% to 15.30April 15, 2026 | msn.comMedia Sentiment Over TimeSNGX, CPIX, and LIXT Company DescriptionsCumberland Pharmaceuticals NASDAQ:CPIX$6.75 +0.79 (+13.26%) Closing price 04:00 PM EasternExtended Trading$6.79 +0.04 (+0.59%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Lixte Biotechnology NASDAQ:LIXT$7.19 +0.54 (+8.12%) Closing price 04:00 PM EasternExtended Trading$7.35 +0.16 (+2.23%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.Soligenix NASDAQ:SNGX$0.41 +0.02 (+3.80%) Closing price 04:00 PM EasternExtended Trading$0.40 -0.02 (-3.66%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab's NASA Win Tests Key Support After Sharp Pullback BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Xcel Energy Stock Offers Stability as Electricity Demand Builds Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
